The clinical and Virology effects of NA inhibitor in influenza virus infections (age; over 4 years old, under 11 years old): an open-label, randomized study.

The clinical and Virology effects of NA inhibitor in influenza virus infections (age; over 4 years old, under 11 years old): an open-label, randomized study. - The clinical and Virology effects of NA inhibitor in influenza virus infections (age; over 4 years old, under 11 years old): an open-label, randomized study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010024

Enrollment

120

Registered

2013-02-14

Start date

2013-01-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood influenza infections

Interventions

Oseltamivir Zanamivir Peramivir Laninamivir

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Age: over 4 years old, under 11 years old. 2)Guardian of the patients with informed consent. 3)Out Patient of febrile symptom. 4)The patient who consulted within 48 hours of fever with over 37.5 degrees. 5)A rapid antigen test of Influenza is positive (type A).

Exclusion criteria

Exclusion criteria: History of hypersensitivity caused by neuraminidase inhibitors. Patients who are deemed to be inappropriate by the investigator.

Design outcomes

Primary

Measure	Time frame
-Time to return to normal body temperature (under 37.5 degrees) -Influenza virus titer (TCID50)	—

Secondary

Measure	Time frame
-Duration of influenza symptoms patients -IC50 in NA inhibition assays of NA inhibitors -Virus mutation after treatment of NA inhibitors	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026